The Week in Review: November 4 – November 10, 2017

Friday, November 10, 2017 News Recap: Canada: Updated List of Physicians in British Columbia Currently Treating Hepatitis B and/or Hepatitis C. HepCBC has updated its list of Doctors in BC who treat HCV and HBV. Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients. Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (T...

The Week in Review: October 27 – November 4, 2017

Friday, November 4, 2017 News Recap: Access to Treatment Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way – Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to me...

Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way

Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to meet that objective — and Canada is not among them. Dr. Jordan Feld, a hepatologist at the Toronto Centre for Liver Disease at the University Health Network, sa

The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

– New Data for First Approved Pan-genotypic Once-Daily Single Tablet Regimen for  Chronic Hepatitis C Virus Infection – MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for updated labeling of EPCLUSA® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults w...

Canada Leads International Indigenous Initiative to Make Progress Towards Global HIV, TB and Hepatitis C Targets

OTTAWA, July 5, 2017 /CNW/ - July 10-12, 2017, the Canadian Aboriginal AIDS Network (CAAN) is bringing together international and domestic stakeholders and Indigenous leaders representing over 14 countries, to share promising practices that highlight progress towards achieving global HIV, TB, and hepatitis C targets in Indigenous communities. "I applaud the leadership and dedication of the people and organizations working to drive down the prevalence of A

Gilead Receives Approval in Canada for VEMLIDY™ (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

MISSISSAUGA, ON, June 19, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for VEMLIDY™ (tenofovir alafenamide, TAF) 25mg tablets, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease. – VEMLIDY is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters C

Critics push back against hepatitis C screening advice, say boomers should be tested

"If we had clear data as to how much the costs of the drugs were going to be ... if we had a very clear sense of what was going on, we would be able to look at this again and reconsider the screening decision." Yes, well the prices have been lowered so what are you waiting for? --CD TORONTO -- When Walter Buchanan learned his brother-in-law needed a liver transplant because of advanced cirrhosis caused by a long-undiagnosed infection with hepatitis C, he ...

Hepatitis C documentary sheds light on best practices

VANCOUVER – To launch National Aboriginal Hepatitis C Month in May, the Canadian Aboriginal AIDS Network (CAAN) is proud to release, Promising Practices in Timiskaming First Nation, the second film in a series of documentaries which showcase community-led initiatives and the power of storytelling to improve health outcomes. This time the camera lens focuses on tackling Hepatitis C with culturally appropriate practices as Indigenous People in Canada are